PMID- 32384518
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 19
DP  - 2020 May
TI  - Baihu Jia Renshen Decoction for type 2 diabetic mellitus: A protocol for 
      systematic review and meta-analysis.
PG  - e20210
LID - 10.1097/MD.0000000000020210 [doi]
LID - e20210
AB  - BACKGROUND: Diabetes mellitus (DM) is one of the main health problems that 
      perplex people all over the world. The prevalence of DM is still increasing in 
      spite of the great efforts have been made to control DM in recent years. Type 2 
      diabetes mellitus (T2DM) is the most common type of diabetes, accounting for 
      about 90% of all DM cases. Traditional Chinese medicine has been used on 
      treatment of DM and diabetic complications in China for many years. Baihu Jia 
      Renshen Decoction (BJRD) is one of the oldest classic prescriptions of 
      traditional Chinese medicine that applied in the field of diabetes' treatment. 
      BJRD is proved to be effective after years of clinical practice and basic 
      research. The application of BJRD improves the overall clinical efficacy of T2DM. 
      Therefore, a systematic review is necessary to provide available evidence for 
      BJRD in therapy of T2DM. METHODS: Different studies from various databases will 
      be involved in this study. Only randomized controlled trials of T2DM patients 
      diagnosed with World Health Organization 1999 diagnostic criteria will be 
      included. We will search the literature in the databases from China Conference 
      Paper Database, manual searching. Electronic database includes PubMed, Embase, 
      Cochrane Library, Web of Science, CNKI (China National Knowledge Internet), 
      WanFang, VIP (Chongqing VIP), and CBM (China Biomedical Literature CDROM 
      Database). The primary outcomes include 2 hour plasma glucose, fasting plasma 
      glucose, hemoglobin A1c, homeostasis model assessment of insulin resistance, and 
      fasting plasma insulin. The secondary outcomes include clinical efficacy and 
      adverse events. Data will be extracted by 2 researchers independently, risk of 
      bias of the meta-analysis will be evaluated based on the Cochrane Handbook for 
      Systematic Reviews of Interventions. All data analysis will be conducted by data 
      statistics software Review Manager V.5.3. and Stata V.12.0. RESULTS: This study 
      will synthesize and provide high-quality evidence based on the data of the 
      currently published BJRD for the treatment of T2DM, in terms of 2 hour plasma 
      glucose, fasting plasma glucose, hemoglobin A1c, homeostasis model assessment of 
      insulin resistance and fasting plasma insulin, clinical efficacy, and safety. 
      CONCLUSION: This systematic review aims to evaluate the benefits and harms of 
      BJRD for the treatment of T2DM reported in randomized controlled trials, and 
      provide more options for clinicians and patients to treat T2DM. REGISTRATION 
      NUMBER: INPLASY202040006.
FAU - Tian, Yuan
AU  - Tian Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Zhong, Wen
AU  - Zhong W
FAU - Zhang, Yuan
AU  - Zhang Y
FAU - Zhou, Linyue
AU  - Zhou L
FAU - Fu, Xiaoxu
AU  - Fu X
FAU - Wang, Lizhen
AU  - Wang L
FAU - Yang, Yan
AU  - Yang Y
FAU - Xie, Chunguang
AU  - Xie C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin
MH  - Humans
MH  - *Panax
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7220408
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/05/10 06:00
MHDA- 2020/06/02 06:00
PMCR- 2020/05/08
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/05/08 00:00 [pmc-release]
AID - 00005792-202005080-00095 [pii]
AID - MD-D-20-03050 [pii]
AID - 10.1097/MD.0000000000020210 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(19):e20210. doi: 10.1097/MD.0000000000020210.